Mobile
+201227693377 - +201227693388 -
+202 22673175
Address
Secondary Trade Building Entrance No. 5, Fifth Area- Sheraton Heliopolis, Cairo.

Lasaromep 40mg

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 
  • Pack

10 FC tablets

  • Composition

Each film coated tablet contains:

 Valsartan                                      40 mg

  • Indication

• Hypertension

Lasaromep  (valsartan) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with  Lasaromep.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Lasaromep  may be used alone or in combination with other antihypertensive agents.

• Heart Failure

Lasaromep  is indicated for the treatment of heart failure (NYHA class II-IV). In a controlled clinical trial, Lasaromep  significantly reduced hospitalizations for heart failure. There is no evidence that Lasaromep  provides added benefits when it is used with an adequate dose of an ACE inhibitor .

• Post-Myocardial Infarction

In clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction, Lasaromep  is indicated to reduce cardiovascular mortality .

Contact Us

Secondary Trade Building Entrance No. 5, Fifth Area- Sheraton Heliopolis, Cairo.
Phone : 00201227693377 - 00201227693388 00202 22673175 - 00202 22673176
Fax : 00202 22674934
Email : Mepaco@mepaco–pharma.net
© Copyright 2022 MEPACO MEDIFOOD. All Rights Reserved. Powered by Fine Arts